Emerging research suggest this peptide, a dual agonist targeting both incretin and another hormone, may represent a significant step forward for body treatment. Initial patient tests have demonstrated impressive decreases in abdominal mass , possibly outperforming other weight-loss therapies . However , additional assessment is needed to check here